The agreement has a provision to increase by another $15 million to $30 million if Comera wishes to. The funds from the sale will go toward Comera’s working capital and fund for general corporate purposes, according to an Aug. 31 Comera news release shared with Becker’s.
“The line of credit provides the opportunity to invest in our pipeline and proprietary formulation platform, SQore, which is designed to transform intravenous biologics into subcutaneous versions that patients can self-administer in a single dose,” said Jeffrey Hackman, president, CEO and chair of Comera. “Strengthening our balance sheet will help us achieve our strategic objectives in the near-term, and we are grateful for Arena’s commitment to Comera’s success.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.